About the Trial TransCode's Phase 1 clinical trial is a multicenter, open-label, dose-escalation and dose-expansion study designed to generate critical data to support evaluation of the safety and ...
Pyxis Oncology announces Phase 1/2 trials for PYX-201, combining it with KEYTRUDA® to treat advanced solid tumors. Pyxis Oncology, Inc. has announced the initiation of two significant clinical ...
About the Trial TransCode's Phase 1 clinical trial is a multicenter, open-label, dose-escalation and dose-expansion study designed to generate critical data to support evaluation of the safety ...
BOSTON - TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a micro-cap RNA oncology company with a market capitalization of $6.22 million, has announced the progression of its Phase 1 clinical trial with ...
MIRAMAR, Fla., Feb. 03, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or the “Company”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical ...
The OCU200 Phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal injection in three cohorts: low dose (0.025 mg), medium dose (0.05 mg ...
SAB BIO to Host Webinar Discussing Topline Results from Phase 1 Trial of SAB-142 for Type 1 Diabetes
SAB BIO will host a webinar on January 28, 2025, to discuss Phase 1 trial data for its T1D therapy, SAB-142. SAB BIO, a clinical-stage biopharmaceutical company, announced it will host a webinar ...
The Phase 1 clinical trial is comprised of two components. In the first component, 72 healthy volunteers have been enrolled in a blinded, randomized, placebo-controlled, staggered, parallel design ...
The first patient has been enrolled in a Phase 1 clinical trial evaluating the safety and tolerability of Rigel Pharmaceuticals’ fostamatinib — a medication approved in the U.S. for treating an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback